Cutaneous leishmaniasis (CL) develops after inoculation of the skin with parasites of the genus Leishmania, transmitted by phlebotomines (sandflies). Every year, CL affects approximately 1-1.5 million people worldwide, with over 90% of the cases occurring in the Middle East and South America. 1 CL is regarded as a parasitic disease caused by Leishmania and no optimal medication protocol is available for this skin infection. Beneficial treatment regimens for CL should be based on experience, efficiency and the toxicity of the drugs in each region. Importantly, it has been clarified that protective immunity against CL is related to induction of Th1/Tc1 immune response, which leads to efficient parasite elimination.
It has been revealed that P-glycoproteins mediate drug resistance to Leishmania and other protozoa and that this is followed by development of cross-resistance to numerous structurally and functionally unrelated drugs.
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Leishmania parasites are obligate intracellular organisms in mammals, and they invade macrophages and dendritic cells. Notably, it has been demonstrated that nitric oxides produced in macrophages possess a crucial role as leishmanicidal agents.
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Ginseng (Panax ginseng) has been used for thousands of years in phytomedicine and it has captured a specific position on the list of the best-selling herbal agents in the world.
11 Ginseng modulates blood pressure, metabolism and immune functions.
12
Interestingly, ginsenosides, which are the major active component of ginseng, have a range of biomedical effects. 13 They are triterpene saponins, and most ginsenosides are composed of a dammarane skeleton (17 carbons in a four-ring structure) with various sugar moieties.
It is noteworthy that ginseng therapy has been shown to stimulate a Th1-like immune response, which improves the course of diseases in animal models. 14 Importantly, ginseng modulates the peripheral blood mononuclear cells and leads to higher IL-12 production. Additionally, elevated IL-12 levels can induce a more potent Th1 immune response.
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IH-901, a new intestinal bacterial metabolite extracted from protopanaxadiol-type ginsenosides, has been observed to suppress ornithine decarboxylase activity dose-dependently in animal skin.
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Protein-arginine N-methyltransferase (protein methylase I) catalyzes methylation of arginyl residues on substrate protein post-translationally. It has been found that Korean red ginseng is able to inhibit protein methylase I activity and, subsequently, polyamines in vitro.
17
Lee et al. demonstrated that total saponin in ginseng and ginsenosides was capable of decreasing the putrescine levels in immobilization-stressed gerbil mice. Notably, an in vitro study has shown that purified Rg1 ginsenosides increase the production of nitric oxide from IFNgamma activated macrophages.
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Ginsenosides have been reported to be inhibitors of 
